Starbucks' quarterly earnings (SBUX) for January-March 2022 were worse than market-wide expectations. According to the company's management, this is due to the pressure of increased expenses on profit, the forecast of which for the 2022 fiscal year has been revised down.
The coffee giant's net profit reached $815.9 million ($0.69 per share) compared with $622.2 million ($0.53 per share) a year earlier. Excluding one-time items, Starbucks earned $0.72 per paper, falling short of the forecasts of analysts surveyed by FactSet at $0.80. The company pointed to higher-than-expected costs across the supply chain and an increase in the number of employees taking sick leave.
During the conference call, Kevin Johnson, CEO of Starbucks, said that the company puts assumptions in its forecasts about the acceleration of inflation by the end of the year, as well as about the persistence of problems in supply chains. As a result, Starbucks plans another increase in prices for its products after their rise in October and January. In general, the increase in costs and the increase in selling prices did not come as a surprise to investors, since inflationary pressures and staff shortages affect all industry participants, and price increases are one of the few measures available to Starbucks to mitigate the negative impact of these factors.
The issuer's net revenue increased by 19% to $8.05 billion, exceeding expectations of $7.95 billion. Global comparable sales increased by 13% over the past quarter. Despite personnel problems, the company was able to report an increase in comparable sales in the United States by 18% compared to the previous year and by 12% over two years. The number of active users of the Starbucks rewards program increased by 21% within 90 days, to 26.4 million people. During the holiday season, consumers usually return to the cafe for gift cards. During the quarter, customers spent more than $3 billion to top up these cards in cash.
Demand outside the US is weaker. International comparable sales fell by 3%, which was caused by a 14% QoQ decline in China (the second largest market for Starbucks). The Celestial Empire has re-imposed restrictions on travel to some cities, faced with another surge in the incidence of COVID-19. It is possible that the epidemic situation in China will continue to worsen, since the omicron strain reached this country much later than it reached the UK or the USA. In particular, this variant of the coronavirus in China was identified only in January 2022. In addition, the Winter Olympic Games will be held in Beijing this year. As a result, the Chinese authorities will take tough measures to curb the spread of COVID-19.
Starbucks has lowered its profit forecast for fiscal year 2022, citing increased costs due to the influence of the omicron strain. Now the company believes that GAAP EPS will decrease by 4-6% (against -4% expected last quarter), and adjusted EPS will grow by 8-10% (against more than +10% expected last quarter).
We are neutral in our assessment of Starbucks' operating performance. In our opinion, sales in the United States and in many European countries will continue to grow due to the economic recovery and the weakening of quarantine restrictions. This is facilitated by the high level of vaccination of the population, as well as a reduction in the number of hospitalizations and deaths caused by COVID-19. Thus, the mobility of citizens at these markets will increase, which, in turn, will lead to an increase in traffic at Starbucks outlets. However, we believe that throughout the year the company will be subjected to inflationary pressure due to the rise in the cost of products, and will also continue to face a shortage of personnel. In addition, emerging markets, including China, remain a concern. In our opinion, the Chinese authorities will not abandon the policy of "zero tolerance" for COVID-19 this year, which will lead to the periodic introduction of quarantine restrictions. At the same time, we would like to note that emerging markets are recovering from the impact of the pandemic more slowly than developed countries, which is largely due to the lower level of vaccination of the population.
Our target price for SBUX paper is $117.